Mission SECU Cancer Center
PUBLIC REPORTING OF OUTCOMES

August 23, 2019   |    Mission Health   |    509 Biltmore Avenue
<table>
<thead>
<tr>
<th>Breast CP3R</th>
<th>Description</th>
<th>CoC Goal</th>
<th>Performance Rate</th>
</tr>
</thead>
</table>
| MASTRT     | Radiation therapy is considered or administered following any mastectomy within 1 year (365 days) of diagnosis of breast cancer for women with ≥4 positive regional lymph nodes.  
(Standard 4.4) | 90%      | 100%             |
| BSCRT      | Radiation is administered within 1 year (365 days) of diagnosis for women under the age of 70 receiving breast conservation surgery for breast cancer.  
(Standard 4.4) Accountability | 90%      | 91%              |
| HT         | Tamoxifen or third generation aromatase inhibitor is considered or administered within 1 year (365 days) of diagnosis for women with AJCC T1c or stage IB-III hormone receptor positive breast cancer.  
(Standard 4.4) Accountability | 90%      | 97.7%            |
| nBx        | Image or palpation-guided needle biopsy to the primary site is performed to establish diagnosis of breast cancer.  
(Standard 4.5) Quality Improvement | 80%      | 97%              |
| MAC        | Combination chemotherapy is considered or administered within 4 months (120 days) of diagnosis for women under 70 with AJCC T1c, or stage II or III hormone receptor negative breast cancer.  
(Standard 4.4) Accountability | N/A      | 96.2%            |

**CP3R Metrics**

% Concordant: Mission SECU Cancer Program, Asheville, NC